Evaluation of ivermectin effects on Covid-19
Phase 3
- Conditions
- Type-2 coronavirus pneumonia.Severe acute respiratory syndrome [SARS]U07.2
- Registration Number
- IRCT20190624043993N2
- Lead Sponsor
- Kermanshah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Definite (clinical and positive PCR) Covid-19 disease
Less than 48 hours have passed since the onset of symptoms
Exclusion Criteria
Underlying liver disease/hepatitis
Underlying hematological disorders
Seizures and encephalopathy
Known allergies to ivermectin
Pregnancy/lactation
Patients who themselves or their legal guardians are reluctant to participate or continue clinical trials
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical response. Timepoint: Day 7 and 14 after study initiation. Method of measurement: Clinical- radiographic.
- Secondary Outcome Measures
Name Time Method Virological response. Timepoint: Day 7. Method of measurement: PCR.